治疗性冲洗液方案治疗根尖周炎(TIPTAP):一项三盲平行组随机对照I/II期试验
该三盲平行组随机对照I/II期试验纳入37名健康成人的40颗单根恒牙,比较17% EDTA与5.25% NaOCl冲洗对无症状根尖周炎1年疗效。结果显示两组有利结局比例分别为94.1%与89.5%,无严重不良事件,EDTA组不良愈合的OR为0.53(95%CI 0.04-6.44,P>.05),IL-6和IL-18在干预组显著更丰富(P<.05)。
要点
- 17% EDTA冲洗1年有利结局94.1%,5.25% NaOCl为89.5%,差异无统计学意义(P>.05)。
- EDTA组不良根尖周愈合OR为0.53(95%CI 0.04-6.44;P>.05)。
- 两组均无严重不良效应,NaOCl组发生2例器械后急性加重(P>.05)。
核心结论
- 促进牙本质细胞外基质溶解的治疗性冲洗液方案1年疗效与传统冲洗方案相当,且无严重不良效应报告。
研究设计与样本
- 三盲平行组随机对照I/II期试验,纳入37名健康成人的40颗单根恒牙,按区组随机分为17% EDTA组(n=20)与5.25% NaOCl组(n=20),所有其他牙髓治疗步骤标准化,两次就诊,氢氧化钙根管内封药14天。
主要发现
- 1年回访率90%(NaOCl组19颗,EDTA组17颗);NaOCl组有利结局89.5%,EDTA组94.1%,P>.05。
- NaOCl组病损体积中位缩小92.5%(IQR 67.33-99.13),EDTA组缩小95.84%(IQR 78.81-100),P>.05。
- EDTA冲洗不良根尖周愈合的OR为0.53(95%CI 0.04-6.44;P>.05)。
- 两组均无严重不良效应或非典型疼痛模式,NaOCl组器械后发生2例急性加重(P>.05)。
- Target-48 panel在两组均检出15种炎症分析物(CCL-2、-3、-4;CSF-1;CXCL-8;HGF;IL-1β、-6、-18;MMP-1、-12;OLR-1;OSM;TNFSF-10;VEGF-A),封药前均降低,此时IL-6和IL-18在干预组显著更丰富(P<.05)。
关键数值与推荐
- 1年疗效采用锥形束CT按二分法标准(有利/不利)评估,基于病损体积变化。
- 统计分析采用符合方案集分析及二元逻辑回归模型,初始α值设为P<.05。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Solubilized endogenous dentine extracellular matrix components (dECMs) are potent mediators in pulp regeneration and could potentially promote similar healing effects in diseased periradicular tissues by upregulating local mesenchymal stem cell-derived regenerative events. AIMS: (1) Determine if endodontic treatment outcomes with irrigation regimes promoting dECM release (17% ethylenediaminetetraacetic acid [EDTA]) are equivalent to conventional regimes (5.25% sodium hypochlorite [NaOCl]) in mature permanent teeth with asymptomatic apical periodontitis. (2) Explore changes in pain scores, expressions of periradicular tissue fluid (PTF)-derived inflammatory mediators, and volumtric changes in lesion size between the different irrigant regimes. METHODS: Forty single-rooted teeth, from 37 healthy adults, were block randomized into parallel groups of irrigation with either 17% EDTA, optimized for dECM solubilization, or 5.25% NaOCl (n = 20). All other aspects of the endodontic protocol were standardized over two visits with 14 days of calcium hydroxide intracanal medicament. Patient-reported pain scores were recorded at six hours and then daily for one week post-instrumentation and post-obturation. PTF samples were collected pre-instrumentation and pre-obturation, where analyte profiles (pg/TPC) were determined using an O-link Target-48 cytokine array. Treatment outcomes were clinically and radiographically assessed with cone beam computed tomography at 1 year using dichotomous criteria (favourable/unfavourable) based on volumetric change in lesion size. Participants, operators and assessors were blinded, and per-protocol analyses were conducted using binary logistic regression models with initial alpha values for statistical comparisons set at p < .05. RESULTS: A 90% recall rate was achieved at one year (NaOCl: 19; EDTA: 17). Favourable outcomes were observed in 89.5% of treatments using NaOCl and 94.1% of treatments using EDTA irrigation, with median lesion volume reductions of 92.5% (IQR: 67.33-99.13) and 95.84% (IQR: 78.81-100), respectively, (p > .05). Odds of unfavourable periradicular healing with EDTA irrigation were 0.53 [95% CI: 0.04-6.44; p > .05]. No serious adverse effects or atypical pain patterns were reported, although two acute exacerbations occurred post-instrumentation with NaOCl irrigation (p > .05). Target-48 panels consistently detected 15 inflammatory analytes in both groups (CCL-2, -3, -4; CSF-1; CXCL-8; HGF; IL-1β, -6, -18; MMP-1, -12; OLR-1; OSM; TNFSF-10; VEGF-A), all of which reduced pre-obturation. At this stage, IL-6 and -18 were significantly more abundant in the intervention group (p < .05). CONCLUSIONS: Therapeutic irrigant regimes promoting dECM solubilization resulted in one-year treatment outcomes equivalent to conventional irrigant protocols with no serious adverse effects reported.
引用
- Virdee SS, Bashir NZ, Grant MM, et al. Therapeutic Irrigant Procedures for Treating Apical Periodontitis (TIPTAP): A triple-blinded parallel-group randomized controlled phase I/II trial. Int Endod J. 2025. PMID: 40229989. doi:10.1111/iej.14233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。